Associated Genetic Biomarkers
TSC2 Loss is present in 0.10% of AACR GENIE cases, with high grade ovarian serous adenocarcinoma, breast invasive ductal carcinoma, pancreatic neuroendocrine neoplasm, bladder urothelial carcinoma, and hepatocellular carcinoma having the greatest prevalence .
TSC2 Loss serves as an inclusion eligibility criterion in 1 clinical trial, of which 0 are open and 1 is closed. Of the trial that contains TSC2 Loss as an inclusion criterion, 1 is phase 2 (0 open).
Trials with TSC2 Loss in the inclusion eligibility criteria most commonly target malignant solid tumor .
Vistusertib is the most frequent therapy in trials with TSC2 Loss as an inclusion criteria .
Significance of TSC2 Loss in Diseases
Malignant Solid Tumor +
TSC2 is altered in 3.6% of malignant solid tumor patients with TSC2 Loss present in 0.1% of all malignant solid tumor patients .
TSC2 Loss is an inclusion criterion in 1 clinical trial for malignant solid tumor, of which 0 are open and 1 is closed. Of the trial that contains TSC2 Loss and malignant solid tumor as inclusion criteria, 1 is phase 2 (0 open) .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. Liu X, Wu C, Li C, and Boerwinkle E. dbNSFP v3.0: A one-stop database of functional predictions and annotations for human nonsynonymous and splice site SNVs. Human Mutation. 2015;37:235-241.
Liu X, Jian X, and Boerwinkle E. dbNSFP: A lightweight database of human nonsynonymous SNPs and their functional predictions. Human Mutation. 2011;32:894-899.
4. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.